Bivalent Inhibitor Development for a Dynamic Epigenetic Tandem Reader Protein Using a Combinatorial Histone Code

McPherson, J. E.; Sneddon, M. S.; Begyinah, R. K.; Babu, K.; Peterson, K. E.; Friess, R. F.; Smith, T. G.; Tretyakova, N.; Fischer, M.; Pomerantz, W. C. K.

doi:10.64898/2026.10.09.758058

bioRxiv · 10.64898/2026.10.09.758058

Bivalent Inhibitor Development for a Dynamic Epigenetic Tandem Reader Protein Using a Combinatorial Histone Code

McPherson, J. E.·Sneddon, M. S.·Begyinah, R. K.·Babu, K.·Peterson, K. E.·Friess, R. F.·Smith, T. G.·Tretyakova, N.·Fischer, M.·Pomerantz, W. C. K.

View original source ↗Export metadata ↓

Abstract

Epigenetic readers are a class of proteins that recognize specific chemical modifications on histones to differentially regulate gene expression. Aberrant expression of readers can drive the progression of many diseases and cancers, making this protein class viable therapeutic targets. Understanding the landscape of histone modifications recognized by reader domains, and the structural mechanisms that drive these molecular recognition events, is crucial for guiding the design of pharmaceutically relevant chemical probes. BPTF contains a plant homeodomain (PHD) finger and tandem bromodomain (BRD). Here, we expand upon previous studies that found the BPTF BRD can engage acetyllysine modifications on the N-terminus of histone H3. We uncover H3K4me3K14ac as the specific modifications recognized by the PHD BRD cassette, which is confirmed by crystallography. Using orthogonal methods, our work explores how these modifications can be read cooperatively, including in cis. We report the first experimental evidence proposing a ligand-induced conformational change between the two reader domains of BPTF, supporting previous computational approaches that have predicted a macromolecular rearrangement. We leverage these structural insights to rationally design a peptide-small molecule conjugate MJ-1 that inhibits both domains of BPTF and overcomes ligandability challenges associated with PHD-finger-containing proteins. The results presented here elucidate the molecular basis of the bivalent recognition of multiply modified histone H3 by BPTF and provide structural insight for developing compounds targeting the PHD finger of BPTF for therapeutic applications.

Explore related subjects

biochemistry Preprint

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

McPherson, J. E., Sneddon, M. S., Begyinah, R. K., Babu, K., Peterson, K. E., Friess, R. F., Smith, T. G., Tretyakova, N., Fischer, M., Pomerantz, W. C. K.. 2026-10-16. Bivalent Inhibitor Development for a Dynamic Epigenetic Tandem Reader Protein Using a Combinatorial Histone Code. https://doi.org/10.64898/2026.10.09.758058

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Investigating Histone Lysine Acetylation and Acetyl-methylation in Mouse Brain using Enhanced Trimethylacetic Anhydride Derivatization Protocol

Histone post-translational modifications (PTMs) are key regulators of gene expression, and mass spectrometry (MS) provides a powerful platform for their characterization and quantification. However, conventional histone sample preparation using derivatization of non-modified lysines by propionic anhydride (PA) presents analytical limitations, including non-detection of short hydrophilic peptides, incomplete chromatographic separation of positional isomers, and masking of endogenous lysine propionylation and butyrylation. Here, we optimized a trimethylacetic anhydride (TMA)-based derivatization workflow to improve histone PTM analysis. Compared with PA derivatization, TMA enhanced the detection of acetylated peptides, particularly short and hydrophilic species, although peptide-dependent ionization biases affected relative peptidoform quantification. We further evaluated the suitability of TMA derivatization for investigating endogenous lysine propionylation and butyrylation. Unexpectedly, we identified lysine acetyl-methylation (Kacme) at seven sites on histone H3 and validated these assignments by targeted MS using synthetic reference peptides. To investigate the metabolic dynamics of Kacme, we performed in vivo isotope tracing in mice administered 13C-labeled glucose. Unlike canonical lysine acetylation, Kacme exhibited minimal incorporation of glucose-derived acetyl groups over 2h, suggesting substantially slower turnover of its acetyl moiety. Collectively, these findings highlight the analytical advantages and quantitative limitations of TMA-based histone derivatization, while revealing Kacme as a metabolically distinct histone modification and expanding the scope of MS-based histone PTM analysis.

biochemistry↗

bioRxiv2026

Binding of a Macrocyclic Nonapeptide Inhibitor to Histone Deacetylase 6

Histone deacetylase 6 (HDAC6) plays an essential role in the regulation of post-translational lysine acetylation. Myriad biological processes depend on the precise regulation of lysine acetylation-deacetylation cycles, and their dysregulation is linked to human pathologies such as cancer and neurodegeneration. Broad-specificity HDAC inhibitors are efficacious in treating disease, but the inhibitors currently approved for clinical use often cause deleterious side effects due to inhibition of multiple HDAC isozymes as well as other zinc enzymes. Cyclic peptides comprise novel platforms that, in principle, can be tailored for affinity and selectivity. A key advantage of cyclic peptide design is the ability to incorporate both canonical and noncanonical amino acids. As part of our program focusing on cyclic peptide HDAC inhibitors, we now report the 1.9-[A] resolution crystal structure of HDAC6 CD2 complexed with macrocyclic nonapeptide 1. The structure reveals zinc coordination by a noncanonical thiolate-containing amino acid, plus direct and water-mediated enzyme-inhibitor hydrogen bonds that contribute to nanomolar inhibitory potency. Structural comparisons with previously reported HDAC6 CD2 complexes with tetrapeptide and octapeptide macrocycles reveal similar networks of direct and water-mediated interactions. Given the surge of interest in cyclic peptide inhibitors, fueled in part by advances in computational design approaches, the crystal structure of the HDAC6 CD2-1 complex sets an important foundation for further development of macrocyclic peptide inhibitors.

biochemistry↗

bioRxiv2026

Identification and targeting of a novel drug pocket in the tumour angiogenesis regulator RhoJ

The Rho GTPase RhoJ is a key regulator of tumour angiogenesis and has been identified as a target for anti-angiogenic drug design. Its high sequence conservation with the related Rho GTPase Cdc42 complicates selective drug discovery. RhoJ has a unique N-terminal extension (Asn2-Lys19) that is absent in Cdc42 and other Rho GTPases. Here, we use molecular dynamics simulations to identify a novel allosteric pocket formed by the RhoJ N-terminus and show that this pocket contributes to interactions with key downstream signalling partners. Structure-based virtual screening of small molecules targeting this pocket identified the antifungal terconazole as a potential binder. Computational docking revealed that terconazole occupies the N-terminal pocket, sharing critical contacts with the interface between RhoJ and PAK3, a key interacting partner. To validate this, we developed an optimized bioluminescence resonance energy transfer (eBRET2)-based biosensor to monitor the interaction between RhoJ and PAK3 in live cells and saw that terconazole disrupted the RhoJ:PAK3 interaction in a dose-dependent manner. Together, our MD results show that the RhoJ N-terminal extension assumes structure on binding to PAK3 and contributes to that interaction, while our cellular biosensor data support targeting this pocket to modulate the RhoJ:PAK3 interaction. The ability of terconazole to bind to the N-terminal pocket and disrupt PAK3 binding provides proof of concept for the specific targeting of RhoJ in the development of novel anti-angiogenic drugs.

biochemistry↗